Annual report pursuant to Section 13 and 15(d)

Stock Incentive Plan (Tables)

v3.22.0.1
Stock Incentive Plan (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Disclosure of Share-based Compensation Arrangements
The Company recorded share-based compensation expense as follows for the years ended December 31, 2021, 2020 and 2019:

Years Ended
December 31,
2021
December 31,
2020
December 31,
2019
Salaries, wages and employee benefits - continuing operations $ 9,108  $ 9,715  $ 10,595 
Salaries, wages and employee benefits - discontinued operation 16  85  179 
Total share-based compensation expense $ 9,124  $ 9,800  $ 10,774 
Schedule of Weighted Average Assumptions
The weighted average grant-date fair value of the stock option awards granted under the Plan and the weighted average assumptions under the Black-Scholes option-pricing model were as follows for the years ended December 31, 2021 and 2020. The Company did not grant stock options during the year ended December 31, 2019.
December 31,
2021
December 31,
2020
Weighted average grant-date fair value $ 18.36  $ 14.79 
Weighted average assumptions under Black-Scholes option model:
Expected dividend yield 1.1  % 1.1  %
Expected stock price volatility 28.9  % 24.1  %
Risk-free interest rate 0.6  % 1.5  %
Expected life of awards (years) 5.8 5.9
Schedule of Stock Option Activity
Stock option transactions during the year ended December 31, 2021 on a continuing operations basis were as follows:
Number of Shares Weighted Average Exercise Price
Outstanding as of January 1 359  $ 55.79 
Granted 39  75.05 
Exercised (56) 53.91 
Forfeited or Canceled —  — 
Outstanding as of December 31 342  $ 58.44 
The following table sets forth the exercise price range, number of shares, weighted average exercise price and remaining contractual lives by groups of similar price on a continuing operations basis as of December 31, 2021:

Stock Options Outstanding Stock Options Exercisable
Range of Exercise Prices Number of Shares Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Exercisable as of December 31, 2021 Weighted Average Exercise Price
$ 43.67  - $ 47.82  107,403  1.6 $ 45.87  107,403  $ 45.87 
50.71  - 59.89  56,689  2.0 55.66  56,689  55.66 
60.42  - 65.96  139,309  4.0 64.60  103,391  64.13 
$ 75.05  - $ 75.05  39,139  6.1 75.05  —  — 
342,540  $ 58.44  267,483  $ 55.01 
Stock option transactions during the year ended December 31, 2021 on a discontinued operation basis were as follows:
Number of Shares Weighted Average Exercise Price
Outstanding as of January 1 14 $ 52.15 
Granted — 
Exercised (14) 52.15 
Forfeited or Canceled — 
Outstanding as of December 31 $ — 
Schedule of Restricted Share Activity
Restricted share transactions on a continuing operations basis for the year ended December 31, 2021 were as follows:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 1 213  $ 62.78 
Granted 109  75.35 
Vested (110) 61.77 
Forfeited (21) 69.08 
Outstanding as of December 31 191  $ 69.84 
Restricted share transactions on a discontinued operation basis for the year ended December 31, 2021 were as follows:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 1 $ 60.83 
Granted —  — 
Vested (4) 60.54 
Forfeited (4) 63.62 
Outstanding as of December 31 —  $ — 
Director restricted share transactions for the year ended December 31, 2021 were as follows:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 1 24  $ 42.88 
Granted 17  93.39 
Vested (26) 47.12 
Forfeited —  — 
Outstanding as of December 31 15  $ 93.46 

Year Ended
December 31,
2021
December 31,
2020
December 31,
2019
Share-based compensation expense for restricted shares $ 1,436  $ 1,026  $ 970 
Excess tax benefit for the vesting of restricted shares $ 342  $ 253  $ 244 
Schedule of Nonvested Performance-based Units Activity The weighted average grant-date fair value of performance awards granted under the Plan and the weighted average assumptions under the Monte Carlo simulation model were as follows for the years ended December 31, 2021, 2020 and 2019:
Year Ended
December 31,
2021
December 31,
2020
December 31,
2019
Weighted average grant-date fair value $ 87.33  $ 69.15  $ 61.42 
Weighted average assumptions under the Monte Carlo simulation model:
Expected stock price volatility 34.5  % 23.5  % 23.4  %
Weighted average risk-free interest rate 0.2  % 1.4  % 2.5  %
Schedule of Performance Award Transactions
Performance award transactions for the year ended December 31, 2021 on a continuing operations basis were as follows assuming target levels of performance:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 1 65  $ 67.62 
Granted 36  87.33 
Earned (11) 72.30 
Forfeited or unearned (11) 70.22 
Outstanding as of December 31 79  $ 75.61 
Schedule of Employee Stock Purchase Plan
Employee stock purchase plan activity and related information was as follows on a continuing operations basis:
Year Ended
December 31, 2021 December 31, 2020 December 31, 2019
Shares purchased by participants under the ESPP 12  14  11 
Average purchase price $ 75.71  $ 44.24  $ 51.50 
Weighted average fair value of each purchase under the ESPP granted1
$ 30.68  $ 20.99  $ 13.68 
Share-based compensation expense for ESPP $ 369  $ 292  $ 150 
1 Equal to the discount from the market value of the common stock at the end of each six month purchase period

Employee stock purchase plan activity and related information was as follows on a discontinued operation basis:
Year Ended
December 31, 2021 December 31, 2020 December 31, 2019
Shares purchased by participants under the ESPP — 
Average purchase price $ —  $ 44.35  $ 51.39 
Weighted average fair value of each purchase under the ESPP granted1
$ —  $ 18.11  $ 13.48 
Share-based compensation expense for ESPP $ —  $ 20  $ 13 
1 Equal to the discount from the market value of the common stock at the end of each six month purchase period